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Abstract
Background and aims. The aim of this retrospective study was to establish whether Fong’s risk score can predict rate of
resectability and whether laparoscopic exploration with ultrasonography can reduce the number of useless laparotomies to
any extent. Material and methods. Fong’s score was calculated for each of the 43 potential resectable patients. We analysed:
the relation between score and resectability; the probability of unnecessary laparotomy with respect to each level of score;
and which of the five Fong parameters was the most indicative of non-resectability. None of our patients was submitted to
preoperative laparoscopic staging. Results. All patients with Fong’s score 0 were submitted to liver resection, whereas only
76.9% with score 1, 58.3% with score 2, and 66.6% with score 3. No patients had score 4 and 5. ‘‘CEA level’’ is the
parameter that best predicts the ‘‘non-resectability’’ of metastases. In the subgroup with score 01, laparoscopy would have
spared 12% of unnecessary laparotomies, whereas in subgroup 23 this percentage would have risen to 38.9. Conclusions.
The above data allowed us to quantify statistically the risk associated with non-resectability of liver metastases in a directly
proportional manner as the score progresses.
Introduction
Metachronous liver metastases arise in 2040% [1] of
patients operated on for colorectal cancer and,
currently, hepatic resection is the most effective
therapy offering 5-year survival rates ranging from
28% to 58% [2]; on the contrary, if a potentially
resectable disease is left untreated, no 5-year survival
is expected [3].
The hepatic surgeon dealing with this category of
patients has to establish the resectability and predict
the potential long-term outcome. In this perspective,
free margins, negative nodes at the hilum and absence
of extrahepatic disease [4] are the current criteria for
hepatic resection. Resectability can be assessed using
imaging techniques such as ultrasound scanning,
contrast-enhanced helical computed tomography
(CT), magnetic resonance imaging (MRI) or positron
emission tomography (PET-CT) [5,6]. A further
recent step improving the assessment of resectability
consists of diagnostic laparoscopy and ultrasonogra-
phy (LUS) of the abdominal cavity and liver, which
could contribute to avoiding unnecessary laparotomy,
as indicated in several series [2,714].
A long-term outcome without liver recurrences
could be assumed by the surgeon using several
prognostic factors published in the literature, such
as Fong’s clinical risk score [15], which is based on
five predictors of poor long-term outcome where only
patients with up to two criteria can have a favorable
prognosis.
The goal of this retrospective study, which includes
patients affected by metachronous liver metastases
from colorectal cancer and who have undergone liver
resection without preoperative LUS, was to establish
whether the Fong clinical risk score could improve
assessment of resectability and the possible contribu-
tion of LUS in the selection of patients scheduled for
liver resection in order to prevent unnecessary laparo-
tomies.
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Material and methods
This retrospective study included patients in follow-
up after curative surgery for colorectal cancer and
referred to our Department between January 1997
and January 2003. All patients suspected for meta-
chronous hepatic metastases based on their CEA
plasma levels and/or US examination were evaluated
using a triphasic helical CT scanning before and after
administration of i.v. contrast material. The hepatic
arterial phase and the portovenous phase were
scanned at 30 and 80 s, respectively, and 5 mm slices
were acquired in the contrast-enhanced phases.
The clinical risk score proposed by Fong [15] (from
0 to 5), based on the absence, presence, or combina-
tion of five factors (from A to E), was calculated for
each potentially resectable patient (Table I). From a
statistical perspective, we therefore analysed: 1) the
presence of a significant relation (pB0.05) between
score and resectability of metastases (Pearson statis-
tical method); 2) the probability of unnecessary
laparotomy with respect to each level of score by
applying the estimate binomial probabilities (Pearson
statistical method); and 3) which of the five Fong
parameters was most indicative of the non-resectabil-
ity of metastases, by applying the estimate binomial
probabilities also in this case (Pearson statistical
method).
At the time of this study, none of our patients in this
group was submitted to preoperative laparoscopic
staging and LUS procedure; laparotomy was per-
formed on the basis of the imaging results, and
resectability was re-evaluated by exploration of the
entire abdominal cavity and liver ultrasonography.
Results
In the period of the study, 47 patients (29 M and 18
F) with a mean age of 62 years (range 3472) were
eligible for liver resection for metastases from colo-
rectal cancer; 4 of these patients refused the procedure
and the remaining 43 were scheduled using the Fong
score (Table I). None had a score of 4 or 5. At
laparotomy, contraindications to resection were found
in 10 cases: 3 of peritoneal metastases, 5 of positive
nodes at the common hepatic artery and celiac trunk,
and 2 cases of further small liver metastases (shown by
intraoperative ultrasonography). All patients with a
score of zero were submitted to liver resection,
whereas only 10 out of 13 patients with a score of 1
(76.9%), 7 out of 12 patients (58.3%) with a score of
2, and finally 4 out of 6 patients (66.6%) with a score
of 3 were submitted to liver resection (Table I).
If from a statistical perspective the relation between
score level and number of resected patients was
not significant (p-value: 0.4056), reliability (p-value:
0.8814) was reported in assessment of the probability
of unnecessary laparotomies with respect to each
score level, i.e. value ranges from 7.3% of score 0 to
29.4% of score 2 (Table II).
With due caution because of the limited sample, the
statistical analysis allowed us to determine, with
regard to the relation between presence of each of
the five Fong factors and resectability of liver metasta-
ses, that parameter E positivity (CEA level 200 ng/
ml) is to a greater extent indicative of non-resectability
(66.67%) than is parameter A (node-positive primary
tumor 5), which influences such assessment the
least (0.00%) (Table III).
The overall rate of resectability was 76.7%. Since
the number of resected patients was 22/25 (Table I) in
the subgroup with score 01, the use of LUS would
have spared 12% (3/25) of unnecessary laparotomies,
whereas in the subgroup with score 23 the number of
resected patients was 11/18 and therefore LUS would
have spared 38.9% (7/18) of unnecessary laparo-
tomies; hence, the preoperative imaging failed the
assessment of resectability in 23.3% of patients (10/
43) who underwent an unnecessary ‘‘open and close’’
laparotomy.
Table I. 43 patients with resectable hepatic metastases.
Score 0 Score 1 Score 2 Score 3
12 patients
12 radical treatment
(100%)
13 patients
10 radical treatment
(76.9%)
12 patients
7 radical treatment
(58.3%)
6 patients
4 radical treatment
(66.6%)
5: B 5: BC 3: BCD
5: C 2: BD 2: CDE
3: D 2: AD 1: ABC
1: CD
1: BA
1: ED
A: node- positive primary tumor5.
B: disease free interval from primary to metastasesB12 months.
C: number of metastases 1.
D: largest metasteses5 cm.
E: carcinoembryonic antigen level200 ng/ml.
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Discussion
In the literature, resectability of hepatic metastases
from colorectal cancer ranges from 10% to 25% [2];
this small percentage is sometimes associated with
clinical motivation in high-risk patients, but in the vast
majority of cases positive nodes at the hilum [1620]
and the impossibility of achieving free margins of
resection [2124] are the current contraindications by
general consent. Furthermore, the number, size, and
distribution of metastases could prevent resection
because of insufficient hepatic functional reserve.
The clinical risk score proposed by Fong in 1999
[15] is based on two imaging factors (number and
size of metastases) and three oncological parameters
(disease-free interval, CEA, node-positive primary
tumor), and the aim of the score was to predict the
long-term outcome of over 1000 patients operated
on for hepatic metastases from colorectal cancer.
Could the oncological parameters contribute to a
higher sensitivity of preoperative staging and there-
fore a more accurate rate of resectability? Consider-
ing our data, it should be taken into account that no
patients with score 4 or 5 were deemed resectable by
us, whereas the number of patients deemed resect-
able with score 3 is lower than the number of
patients with score 0, 1, or 2. Furthermore, in our
patients with the best and worst scores (0 and 3), the
rate of resectability (100% and 66%) is directly
correspondent (Table I), even though there is no
statistical significance (p-value: 0.4056). A good
correspondence was also found in score 1 (76.9%),
which is worse than score 0 but better than score
23; the only doubtful results concern patients with
score 2 (58.3%), worse than score 3; however, in the
group with score 2, widespread small peritoneal
metastases undetected by imaging were found in
the 5 non-resected patients, which did not modify
Fong’s oncological parameters.
The above data allow us to quantify statistically the
risk associated with non-resectability of liver metas-
tases in a directly proportional manner as the score
progresses from 0 to 2 (Table II). Therefore, the CEA
level positivity (CEA level 200 ng/ml), while essen-
tial in evaluating the long-term prognosis of patients
who underwent resection of colorectal liver metas-
tases [4,2527], is the parameter that best predicts the
non-resectability of liver metastases, whereas the para-
meter that least influences the assessment of non-
resectability is the presence of positive nodes 5 of
the primary tumor (Table III).
Moreover, preoperative imaging (CT and MRI)
frequently understages metastases, because it is often
difficult to find extrahepatic diseases such as perito-
neal metastases, certain positive nodes or small liver
metastases [2831], so about 20% of patients undergo
unnecessary laparotomy [13]. Even CT-PET, though
promising [32], still provides uncertain data, and
while it seems to have superior sensitivity, a poor
specificity is also reported [8,33].
In the past few years, in order to reduce the
percentage of patients undergoing unnecessary lapar-
otomy, resulting in morbidity, rising costs, and
delayed chemotherapies [2], the use of LUS has
gained an established role. As to the use of laparo-
scopy and LUS, presuming that this procedure of
staging was effective in all patients, in our series the
total number of unnecessary laparotomies would have
been remarkable (23.2%) even if lower than Kahn’s
[7] and Rahusen’s [14] experiences (39% and 38%,
respectively), and higher than Grobmyer’s [10] (10%)
and similar to Pilkington’s [8] experience (21%).
Furthermore, the percentage of spared unnecessary
operations would be higher in higher-risk patients; in
fact, in subgroup 01, we would have saved 12% of
Table III. Correlation between Fong’s factors and resectability.
Factors No resectability
Probability of
no resectability Resectability
Probability of
resectability
A 0 0.000% 4 100.00%
B 7 60.21% 10 39.79%
C 7 60.21% 10 39.79%
D 3 61.41% 11 38.59%
E 2 66.67% 1 33.33%
A: node- positive primary tumor5.
B: disease free interval from primary to metastasesB12 months.
C: number of metastases 1.
D: largest metasteses5 cm.
E: carcinoembryonic antigen level200 ng/ml.
Table II. Correlation between Fong’s score and ‘‘open and close’’
laparotomy.
Score
Probability of ‘‘open
and close’’ laparotomy
0 0.073267
1 0.218849
2 0.294167
3 0.234315
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laparotomies as opposed to 38% in subgroup 23.
These data and the literature [2,10,12,13] lead us to
consider that it would be useful to perform laparo-
scopic staging only on patients ‘‘at risk,’’ namely
patients with higher scores.
In conclusion, we believe that the higher the Fong
score, the higher the risk of ‘‘open and close’’
laparotomies. Among Fong’s parameters, CEA posi-
tivity (above 200 ng/ml) is, in our case history, the
factor that should give us the most reason to consider
the possibility of non-resection. Additionally, laparo-
scopic staging, because of a direct visualization of
suspected nodes at the hilum and/or small metastases
on the peritoneal surface and the possible sampling, as
well as the well-known effectiveness of LUS with
regard to metastatic liver disease, can contribute to
avoiding a considerable number of unnecessary la-
parotomies and developing a therapy guideline ran-
ging from early resection to a ‘‘test of time’’ with
systemic or locoregional chemotherapies and further
evaluation, comprehensive of a final assessment of
unresectability.
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